Related Experiment Video
Updated: May 20, 2026

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
Published on: September 2, 2020
Targeting TRPV1 for pain relief: limits, losers and laurels
Arpad Szallasi1, Mohamed Sheta
1Monmouth Medical Center, Pathology, Long Branch, USA. aszallasi@sbhcs.com
Introduction:
With 336 reviews, the capsaicin receptor TRPV1 arguably represent today's most extensively reviewed analgesic target. TRPV1 is strategically located at the peripheral terminals of primary sensory neurons where pain is generated. TRPV1 as a target for analgesic drugs has been validated in preclinical studies.
Areas Covered:
The therapeutic potential of targeting TRPV1 by agonists and antagonists for pain relief is discussed based on our experience and a critical review of the literature. Strategies to overcome adverse effects are explored.
Expert Opinion:
Since its discovery in 1997, TRPV1 has run the gamut from excitement to disappointment to cautious optimism. Topical capsaicin has been disappointing for pain relief. By contrast, intrathecal resiniferatoxin is currently undergoing clinical trials in patients with intractable cancer pain. Some of the small-molecule TRPV1 antagonists have successfully passed Phase I safety and tolerability studies in healthy volunteers into Phase II studies to access efficacy in patients. Others showed worrisome unforeseen adverse effects, most important, hyperthermia and impaired noxious heat sensation. We conclude that TRPV1 blockade and desensitization are two promising, complimentary approaches for pain relief. Despite the roadblocks, TRPV1 remains a powerful tool in pain research and a promising therapeutic target.
Insights
Targeting the capsaicin receptor TRPV1 shows promise for pain relief. While topical capsaicin has limitations, new strategies like TRPV1 blockade and desensitization offer therapeutic potential.
Area of Science:
- Pain research
- Neuroscience
- Pharmacology
Background:
- The capsaicin receptor TRPV1 is a key target for pain management, located on sensory neurons where pain signals originate.
- Preclinical studies have validated TRPV1 as a viable target for developing analgesic drugs.
Purpose of the Study:
- To discuss the therapeutic potential of targeting TRPV1 using agonists and antagonists for pain relief.
- To review strategies for mitigating adverse effects associated with TRPV1-targeting therapies.
Main Methods:
- Literature review and expert analysis of TRPV1 targeting strategies.
- Evaluation of clinical trial data for TRPV1-based pain treatments.
Main Results:
- Topical capsaicin has shown limited success for pain relief.
- Intrathecal resiniferatoxin is in clinical trials for cancer pain.
- Some small-molecule TRPV1 antagonists have advanced to Phase II trials, while others exhibited adverse effects like hyperthermia.
Conclusions:
- TRPV1 blockade and desensitization are promising, complementary approaches for pain management.
- Despite challenges, TRPV1 remains a significant target in pain research and therapeutic development.
Related Concept Videos
Analgesia and Pain Management
Thermosensation
Nociception
Pain
Local Anesthetics: Differential Sensitivity of Nerve Fibers
